Edwards Lifesciences is moving higher on an earnings-and-guidance reset following its first-quarter update dated April 23, 2026. The company posted Q1 sales of $1.65 billion (12.7% constant-currency growth) and adjusted EPS of $0.78, then raised full-year 2026 constant-currency sales growth guidance to 9%–11% (from 8%–10%) and increased the midpoint of adjusted EPS guidance to $2.95–$3.05 (from $2.90–$3.05). (s27.q4cdn.com)

The quarter’s biggest underpinning was the company’s core TAVR franchise, where Q1 sales rose to $1.20 billion (11.0% constant currency). Edwards also raised its full-year 2026 TAVR sales growth outlook to 7%–9% (from 6%–8%), pointing to solid U.S. demand and faster growth outside the U.S., helped by competitive dynamics in Europe. (s27.q4cdn.com)

Beyond TAVR, Edwards reported Q1 TMTT sales of $173 million, and highlighted continued adoption across EVOQUE and PASCAL as well as the U.S. FDA approval of SAPIEN M3 for mitral replacement. The company also disclosed completing a $500 million accelerated share repurchase during the quarter, with roughly $1.5 billion remaining under authorization—an incremental tailwind for per-share optics alongside the raised EPS view. (s27.q4cdn.com)